Lynn Kirkpatrick
Women enabling science to reach the people who need it

Lynn Kirkpatrick

Lynn Kirkpatrick
CEO

Ensysce

JLABS @ San Diego

What is the problem you're trying to solve?

The abuse of opioid pain medication has become an epidemic in the United States. However, there are still over 100 million people living with chronic pain that need effective medication that will not lead to addiction and abuse. Ensysce is developing just that with its BiO-MD TM and MPAR TM platforms of pain products.

How is what you're doing different than other attempts to solve this problem?

The Ensysce BiO-MD TM approach provides a Chemical Barrier to abuse" rather than just reformulation opioid products. Our products are only activated when taken orally, they can not be extracted with 'kitchen Chemistry' to abuse, and we have the only Multi-Pill Abuse Resistant overdose prevention technology available. We have removed all opportunity to abuse by inhaling, injecting and chewing our opioid products yet we still provide this potent pain medication that many patients need to function.

Why are you passionate about what you're working on?

The opportunity to have social impact as well as provide a medical need is a rare opportunity. These products are disruptive in the industry and I am now seeing their potential in the clinic.

What achievement are you most proud of?

I have been able to discover and clinically develop a number of highly novel drugs that have improved patients lives.